导师风采
杨仁池
个人信息
Personal Information
- 性别：男
- 导师类型：博士生导师
- 职称：主任医师
- 该职称任职时间：20030901
联系方式
Contact Information
- 所属院系：血液病医院（天津）
- 所属专业：
- 邮箱 : rcyang65@163.com
- 工作电话 : 022-23909122
个人简介
Personal Profile
杨仁池，男，1965年8月16日出生。医学博士，主任医师，博士研究生导师。现为中国医药教育协会止血与血栓分会副主任委员，中国研究型医院学会罕见病分会常务理事，中华医学会血液学分会第十一届委员会委员，中华医学会血液学分会止血与血栓学组副组长。2011-2012年度卫生部有突出贡献中青年专家，国务院政府特殊津贴专家。亚太血友病工作组指导委员会成员，Haemophilia杂志中文版主编，中华血液学杂志编委，天津医药杂志编委，临床内科杂志编委，临床血液学杂志编委，国际输血及血液学杂志编委，罕少疾病杂志编委。《中华医学百科全书》血液病学卷编委。全国高等医学院校教材《内科学》编委。
团队简介
Team Profile
待补充更新
- 研究方向Research Directions
ITP发病机理,凝血因子抑制物发生机理
- 在校研究生Current Graduate Students
硕士研究生 1 名，博士研究生 4 名
- 科研项目Research Projects
| # | 项目名称 | 起止日期 | 金额 | 项目类型 | 本人角色 |
|---|---|---|---|---|---|
| 1 | 利用单细胞免疫组库测序技术评估脾切除对ITP患者免疫状态的影响并鉴定疗效预测指标 | 2022-01-01 —— 2025-12-31 | 55万元 | 主持在研的国家或省部级科研项目 | 主持者 |
| 2 | 中国罕见病的精准诊疗研究 | 2021-10 —— 2025-12 | 800万元 | 参与在研的国家或省部级科研项目 | 参与者 |
| 3 | 腺相关病毒载体载体表达人凝血因子IX基因治疗技术治疗血友病B的临床探索 | 2019-11 —— 2021-10 | 40万元 | 主持在研的国家或省部级科研项目 | 主持人 |
- 发表论文Papers
| # | 论文题目 | 期刊名称 | 发表年份 | 论文署名 |
|---|---|---|---|---|
| 1 | Women and girls with haemophilia: A retrospective cohort study in China. | Haemophilia | 2023-07-07 | 杨仁池 |
| 2 | Demographics, clinical profile and treatment landscape of patients with haemophilia B in China | Haemophilia | 2023-07-07 | 杨仁池 |
| 3 | Outcome of CARE: a 6-year national registry of acquired haemophilia A in China | Br J Haematol | 2022-06-02 | 杨仁池 |
| 4 | Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: results from an open-label extension study | J Thromb Haemost | 2022-06-02 | 杨仁池 |
| 5 | Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A. | Haemophilia | 2023-07-07 | 杨仁池 |
| 6 | Prophylactic emicizumab for hemophilia A in the Asia-Pacific region: A randomized study (HAVEN 5) | Res Pract Thromb Haemost | 2023-07-07 | 杨仁池 |
| 7 | Risk factors for inhibitors in hemophilia A based on RNA-seq and DNA methylation | Res Pract Thromb Haemost | 2023-07-07 | 杨仁池 |
| 8 | Patients with haemophilia A with inhibitors in China: a national real-world analysis and follow-up | Br J Haematol | 2022-06-02 | 杨仁池 |
| 9 | CD70-silenced dendritic cells induce immune tolerance in immune thrombocytopenia patients. | Br J Haematol | 2022-06-02 | 杨仁池 |
| 10 | Role of bone marrow-derived mesenchymal stem cell defects in CD8 CD28- suppressor T-lymphocyte induction in patients with immune thrombocytopenia and associated mechanisms | Br J Haematol | 2022-06-02 | 杨仁池 |
| 11 | A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia | J Hematol Oncol | 2022-06-02 | 杨仁池 |
| 12 | Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia | Br J Haematol | 2022-06-02 | 杨仁池 |
| 13 | Factor IX inhibitors in haemophilia B: A report of National Haemophilia Registry in China. | Haemophilia | 2023-07-07 | 杨仁池 |
| 14 | Integrin β3 Deficiency Results in Hypertriglyceridemia via Disrupting LPL (Lipoprotein Lipase) Secretion. | Arterioscler Thromb Vasc Biol | 2022-06-02 | 杨仁池 |
| 15 | Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial | Lancet Haematol | 2022-06-02 | 杨仁池 |
| 16 | Analysis of hospitalization of people with hemophilia-12 years of experience in a single center | Res Pract Thromb Haemost | 2023-07-07 | 杨仁池 |
| 17 | Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics study | Platelets | 2023-07-07 | 杨仁池 |
| 18 | Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study | Lancet Haematol | 2023-07-07 | 杨仁池 |
| 19 | Preclinical studies of a factor X activator and a phase 1 trial for hemophilia patients with inhibitors. | J Thromb Haemost | 2023-07-07 | 杨仁池 |
| 20 | Multilevel defects in the hematopoietic niche in essential thrombocythemia | Haematologica | 2022-06-02 | 杨仁池 |
| 21 | Factor VII deficiency in China: Phenotype, genotype and current status of management. | Br J Haematol | 2023-02 | 通讯作者 |
| 22 | Current status of haemophilia inhibitor management in mainland China: a haemophilia treatment centres survey on treatment preferences and real-world clinical practices. | Br J Haematol | 2021-08 | 通讯作者 |
| 23 | Inhibitors: Diagnostic challenges, unknowns of inhibitor development, treatment of bleeding and surgery, and insights into diagnosis and treatment in China. | Haemophilia | 2022-05 | 共一作者 |
| 24 | Health-related quality of life among adults with haemophilia in China: A comparison with age-matched general population. | Haemophilia | 2022-09 | 通讯作者 |
| 25 | Pharmacokinetic, efficacy and safety evaluation of B-domain-deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A. | Haemophilia | 2021-09 | 通讯作者 |
| 26 | Real-world analysis of haemophilia patients in China: A single centre's experience. | Haemophilia | 2020-05 | 通讯作者 |
| 27 | Current and emerging treatments for immune thrombocytopenia | Expert Rev Hematol | 2019-12 | 通讯作者 |
| 28 | IP-10 and MCP-1 gene polymorphisms in Chinese patients with chronic immune thrombocytopenia. | Autoimmunity | 2019-09 | 通讯作者 |
| 29 | A novel SERPINC1 frameshift mutation in two antithrombin deficiency families. | Int J Lab Hematol | 2019-08 | 通讯作者 |
| 30 | Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophiliaA enrolled in the LEOPOLD II trial. | Haemophilia | 2019-05 | 通讯作者 |
| 31 | Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS). | Haemophilia | 2019-05 | 通讯作者 |
| 32 | CCR6 defines a subset of activated memory T cells of Th 17 potential in immune thrombocytopenia. | Clin Exp Immunol. | 2019-03 | 通讯作者 |
- 科研获奖Research Awards
| # | 获奖证书编号 | 奖项名称 | 获奖级别 | 获奖类别 | 获奖等级 | 获奖日期 | 颁奖单位 | 本单位是否为第一完成单位 | 完成单位排名 | 本人排序 | 备注 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2021LC0126R3 | 血小板疾病的精确诊断和定向干预 | 省部级以下 | 华夏医学科技奖-三等奖 | 三等奖 | 2021-12-07 | 中国医疗保健国际交流促进会 | 是 | 1 | 2 |
- 研究成果Research Findings
| # | 成果类型 | 项目/专利/新品种名称 |
|---|---|---|
| 1 | 出版高水平专著 | 血液病诊疗规范 |
| 2 | 出版高水平专著 | 中国血友病管理指南（2021版） |
| 3 | 出版高水平专著 | 免疫性血小板减少症：医患不同的视角 |
| 4 | 出版高水平专著 | 血液学名词 |
| 5 | 出版高水平专著 | 邓家栋临床血液学 |
| 6 | 出版高水平专著 | 血小板减少症经典病例 |
| 7 | 出版高水平专著 | 血栓与止血标准数据集（2021年版） |
| 8 | 出版高水平专著 | 血液病临床输血 |
| 9 | 出版高水平专著 | 血液系统疾病诊疗规范 |
| 10 | 出版高水平专著 | 罕见病学 |